화학요법 유발성 빈혈 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 질환 유형별, 치료 유형별, 약제 유형별, 최종사용자별, 지역별, 경쟁(2021-2031년)

The Global Chemotherapy-Induced Anemia Market is projected to expand from USD 2.86 Billion in 2025 to USD 4.33 Billion by 2031, reflecting a compound annual growth rate of 7.16%. Therapeutics within this sector, including erythropoiesis-stimulating agents, iron supplements, and red blood cell transfusions, serve to correct low hemoglobin levels caused by myelosuppressive cancer treatments. The primary driver of this market trajectory is the increasing global prevalence of oncological conditions that necessitate aggressive cytotoxic protocols, which typically deplete red blood cell counts. According to the American Cancer Society, an estimated 2,041,910 new cancer cases were projected to occur in the United States in 2025, indicating a growing patient population that requires consistent anemia management.

However, the industry faces significant hurdles related to the safety profiles of current pharmaceutical treatments. Regulatory bodies have imposed strict guidelines and black box warnings on erythropoiesis-stimulating agents due to heightened risks of cardiovascular events and potential tumor progression, limiting their unrestricted use. These safety concerns compel healthcare professionals to adopt conservative dosing strategies and frequently search for alternative management methods, which ultimately constrains the global market's overall revenue potential.

Market Driver

The rising global incidence of cancer acts as a major catalyst for the chemotherapy-induced anemia market, as increasing malignancies lead to greater utilization of myelosuppressive therapies. This growing patient base demands ongoing supportive care interventions, such as erythropoiesis-stimulating agents and iron replacement therapies, to stabilize hemoglobin levels and ensure adherence to treatment schedules. According to a February 2024 press release by the International Agency for Research on Cancer titled 'Global cancer burden growing,' new cancer cases are predicted to exceed 35 million by 2050, representing a 77% increase from the estimated 20 million cases in 2022. Such demographic shifts necessitate scalable anemia management protocols to support aggressive cytotoxic regimens, driving volume growth for therapeutic manufacturers.

Concurrently, a strong pipeline of therapeutics with novel mechanisms of action is propelling the sector forward by offering treatments that lower transfusion dependence and mitigate the safety risks of older options. Developers are commercializing agents that target specific bone marrow failure pathways, diversifying management strategies beyond standard erythropoietin production. For example, Geron Corporation announced in June 2024 that the FDA approved imetelstat for treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes. This ongoing innovation fosters broader market reach, as reflected in Sandoz's 2024 report, which noted a 29% constant currency growth in biosimilars net sales during the first half of the year, highlighting the expanding commercial footprint of supportive oncology therapeutics.

Market Challenge

Significant safety concerns regarding erythropoiesis-stimulating agents represent a critical obstacle to the expansion of the Global Chemotherapy-Induced Anemia Market. Regulatory agencies have enforced strict black box warnings that emphasize increased risks of severe cardiovascular events and potential tumor progression linked to these drugs. These safety issues force healthcare providers to exercise extreme caution in prescribing, often restricting treatment to only the most severe cases or opting for observation over pharmaceutical intervention. Such regulatory stringency impedes market growth by artificially reducing prescription volumes and limiting the eligible addressable patient population.

As a result, this cautious clinical approach leads to substantial under-treatment, preventing the market from addressing the full extent of patient demand. Recent clinical data confirms a discrepancy between disease prevalence and therapeutic use. An analysis by the National Comprehensive Cancer Network in 2024 involving patients with solid tumors indicated that while 44% experienced anemia within six months of diagnosis, fewer than 40% of those affected received any form of directed treatment. These low intervention rates illustrate how safety-driven barriers actively restrict therapeutic utilization and curb the sector's overall revenue potential.

Market Trends

The increasing adoption of cost-efficient biosimilar erythropoiesis-stimulating agents is fundamentally transforming the market landscape as healthcare providers balance financial sustainability with clinical outcomes. The expiration of patents for originator biologics has triggered a shift, with payers and institutions mandating the use of value-based biosimilars for chemotherapy-induced anemia management. This transition is driven by the necessity to mitigate the high economic burden of supportive oncology care, resulting in aggressive formulary adjustments favoring these lower-cost alternatives. According to Amgen's financial results released in February 2025, sales of established products like Epogen and Aranesp fell by 19% for the full year 2024, largely due to volume declines and lower prices caused by intense biosimilar competition.

Simultaneously, there is a growing preference for intravenous iron therapies, utilized either alone or in combination with erythropoiesis-stimulating agents, to improve hemoglobin response and lower safety risks. Clinical protocols are increasingly incorporating intravenous iron to rapidly optimize iron stores, addressing functional iron deficiency in cancer patients and reducing reliance on red blood cell transfusions. This strategy enables practitioners to reduce the dosage of stimulating agents, thereby minimizing cardiovascular risks while maintaining efficacy. As noted in CSL Limited's 2024 Annual Report published in August 2024, the intravenous iron market is set for continued volume growth, as approximately 85% of eligible patients do not currently receive this treatment, indicating a major untapped opportunity for therapeutic expansion.

Key Market Players

• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• Panacea Biotec Limited
• SBI Pharmaceuticals Co., Ltd
• Sumitomo Dainippon Pharma Co., Ltd.
• PharmaEssentia Corp.
• PhytoHealth Corp
• UBI Pharma Inc.
• Amgen Inc.
• Astellas Pharma Inc.

Report Scope

In this report, the Global Chemotherapy-Induced Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chemotherapy-Induced Anemia Market, By Disease Type

• Mild Anemia
• Moderate Anemia
• Severe Anemia

Chemotherapy-Induced Anemia Market, By Treatment Type

• RBC Transfusions
• Erythropoiesis-stimulating agents (ESAs)
• Iron Supplementation

Chemotherapy-Induced Anemia Market, By Drug Type

• Epogen Injection
• Procrit Injection
• Androxy Oral
• Aranesp injection
• Epoetin Alfa Injection
• Others

Chemotherapy-Induced Anemia Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Chemotherapy-Induced Anemia Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chemotherapy-Induced Anemia Market.

Available Customizations:

Global Chemotherapy-Induced Anemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chemotherapy-Induced Anemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Mild Anemia, Moderate Anemia, Severe Anemia)
  • 5.2.2. By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation)
  • 5.2.3. By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Chemotherapy-Induced Anemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Drug Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chemotherapy-Induced Anemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Drug Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Chemotherapy-Induced Anemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Drug Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Chemotherapy-Induced Anemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Drug Type
      • 6.3.3.2.4. By End User

7. Europe Chemotherapy-Induced Anemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Drug Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chemotherapy-Induced Anemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Drug Type
      • 7.3.1.2.4. By End User
  • 7.3.2. France Chemotherapy-Induced Anemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Drug Type
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Chemotherapy-Induced Anemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Drug Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Chemotherapy-Induced Anemia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Drug Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Chemotherapy-Induced Anemia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Drug Type
      • 7.3.5.2.4. By End User

8. Asia Pacific Chemotherapy-Induced Anemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Drug Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Chemotherapy-Induced Anemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Drug Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Chemotherapy-Induced Anemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Drug Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Chemotherapy-Induced Anemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Drug Type
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Chemotherapy-Induced Anemia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Drug Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Chemotherapy-Induced Anemia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Drug Type
      • 8.3.5.2.4. By End User

9. Middle East & Africa Chemotherapy-Induced Anemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Drug Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Chemotherapy-Induced Anemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Drug Type
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Chemotherapy-Induced Anemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Drug Type
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Chemotherapy-Induced Anemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Drug Type
      • 9.3.3.2.4. By End User

10. South America Chemotherapy-Induced Anemia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Drug Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Chemotherapy-Induced Anemia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Drug Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Chemotherapy-Induced Anemia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Drug Type
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Chemotherapy-Induced Anemia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Drug Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Chemotherapy-Induced Anemia Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Dr. Reddy's Laboratories Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Panacea Biotec Limited
• 15.4. SBI Pharmaceuticals Co., Ltd
• 15.5. Sumitomo Dainippon Pharma Co., Ltd.
• 15.6. PharmaEssentia Corp.
• 15.7. PhytoHealth Corp
• 15.8. UBI Pharma Inc.
• 15.9. Amgen Inc.
• 15.10. Astellas Pharma Inc.

16. Strategic Recommendations

17. About Us & Disclaimer